Biocon to merge with Biocon Biologics for $5.5 billion
after close1 source ↓written by the desknot a recommendation
- deal valued
- $5.5 billion
Biocon will fully integrate Biocon Biologics as a wholly owned subsidiary in a deal valued at $5.5 billion. This merger is seen as the most value-accretive option following a negative market reaction to the Viatris acquisition. The combined entity aims to enhance financial metrics and unlock synergies across various sectors.
Not investment advice. For informational purposes only.